SI2483271T1 - PIRAZOLIN DIOACTIVE DERIVATIVES AS NADPH-OXIDESHHAN INHIBITORS - Google Patents
PIRAZOLIN DIOACTIVE DERIVATIVES AS NADPH-OXIDESHHAN INHIBITORS Download PDFInfo
- Publication number
- SI2483271T1 SI2483271T1 SI201031580T SI201031580T SI2483271T1 SI 2483271 T1 SI2483271 T1 SI 2483271T1 SI 201031580 T SI201031580 T SI 201031580T SI 201031580 T SI201031580 T SI 201031580T SI 2483271 T1 SI2483271 T1 SI 2483271T1
- Authority
- SI
- Slovenia
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- heteroaryl
- alkenyl
- Prior art date
Links
- CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 title claims abstract 5
- 108010002998 NADPH Oxidases Proteins 0.000 title claims abstract 3
- 102000004722 NADPH Oxidases Human genes 0.000 title claims abstract 3
- 239000003112 inhibitor Substances 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 12
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 10
- -1 amino, aminosulfonyl Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- AQVJNNMDCSWPMV-UHFFFAOYSA-N 2,7-dihydropyrido[1,2-a][1,4]diazepine-1,5-dione Chemical compound C1(C=2N(C(C=CN1)=O)CC=CC=2)=O AQVJNNMDCSWPMV-UHFFFAOYSA-N 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- XCEHGPJYDIOHTC-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-(pyridin-2-ylmethyl)-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4N=CC=CC=4)CCCN3C(=O)C=C2N1 XCEHGPJYDIOHTC-UHFFFAOYSA-N 0.000 claims 1
- YTGBUSQTIGZPPO-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(2-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 YTGBUSQTIGZPPO-UHFFFAOYSA-N 0.000 claims 1
- GNVGXVJPFSNSKT-UHFFFAOYSA-N 2-(2-chlorophenyl)-3,7,8,9,10,11-hexahydropyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CNCCCN3C(=O)C=C2N1 GNVGXVJPFSNSKT-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- VIRAQJQGFAPWHE-UHFFFAOYSA-N 5,7-dihydropyrido[1,2-a][1,4]diazepine-10-carboxylic acid Chemical compound C1=NC=CCN2CC=CC(C(=O)O)=C21 VIRAQJQGFAPWHE-UHFFFAOYSA-N 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004953 trihalomethyl group Chemical group 0.000 claims 1
- 102100021217 Dual oxidase 2 Human genes 0.000 abstract 1
- 101000968308 Homo sapiens Dual oxidase 1 Proteins 0.000 abstract 1
- 101000968305 Homo sapiens Dual oxidase 2 Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09171466A EP2305679A1 (en) | 2009-09-28 | 2009-09-28 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| PCT/IB2010/054329 WO2011036651A1 (en) | 2009-09-28 | 2010-09-27 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| EP10782688.5A EP2483271B1 (en) | 2009-09-28 | 2010-09-27 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2483271T1 true SI2483271T1 (en) | 2018-01-31 |
Family
ID=41347804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201031580T SI2483271T1 (en) | 2009-09-28 | 2010-09-27 | PIRAZOLIN DIOACTIVE DERIVATIVES AS NADPH-OXIDESHHAN INHIBITORS |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9394306B2 (enExample) |
| EP (2) | EP2305679A1 (enExample) |
| JP (1) | JP5707406B2 (enExample) |
| KR (1) | KR101791273B1 (enExample) |
| CN (1) | CN102686590B (enExample) |
| AU (1) | AU2010299487B2 (enExample) |
| BR (1) | BR112012004208A2 (enExample) |
| CA (1) | CA2770278C (enExample) |
| CY (1) | CY1119780T1 (enExample) |
| DK (1) | DK2483271T3 (enExample) |
| ES (1) | ES2644857T3 (enExample) |
| HR (1) | HRP20171638T1 (enExample) |
| HU (1) | HUE035058T2 (enExample) |
| IL (1) | IL218814A0 (enExample) |
| LT (1) | LT2483271T (enExample) |
| ME (1) | ME03040B (enExample) |
| NO (1) | NO2483271T3 (enExample) |
| PL (1) | PL2483271T3 (enExample) |
| PT (1) | PT2483271T (enExample) |
| RS (1) | RS56542B1 (enExample) |
| RU (1) | RU2569855C2 (enExample) |
| SI (1) | SI2483271T1 (enExample) |
| SM (1) | SMT201700541T1 (enExample) |
| WO (1) | WO2011036651A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| WO2013078261A1 (en) | 2011-11-22 | 2013-05-30 | The University Of Maryland, Baltimore | Treatment of muscular conditions and muscular dystrophies |
| WO2013135803A1 (en) * | 2012-03-16 | 2013-09-19 | Glucox Biotech Ab | Thiophene-based compounds exhibiting nox4 inhibitory activity and use thereof in therapy |
| EP2911667B1 (en) | 2012-10-24 | 2017-02-22 | Glucox Biotech AB | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase |
| EP2857399A1 (en) | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
| JP2018505226A (ja) | 2015-02-16 | 2018-02-22 | グルコックス・バイオテック・アーベー | Ｎ２−（３，４−ジメチルフェニル）−６−（（４−（ｐ−トリル）ピペラジン−１−イル）メチル）−１，３，５−トリアジン−２，４−ジアミン |
| EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
| CN111194215B (zh) | 2017-08-04 | 2024-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2023101418A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3931407A (en) | 1973-03-01 | 1976-01-06 | American Hoechst Corporation | Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent |
| DE3728278A1 (de) | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
| DE19518082A1 (de) | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one |
| US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| AU6320998A (en) | 1997-02-21 | 1998-09-09 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
| IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
| EP1396493A4 (en) | 2001-04-26 | 2005-08-03 | Ajinomoto Kk | HETEROCYCLIC COMPOUNDS |
| WO2003091256A1 (en) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| WO2004005267A2 (en) | 2002-07-03 | 2004-01-15 | Janssen Pharmaceutica, N.V. | Heteroaryl compounds useful in treating inflammatory disorders |
| NZ542059A (en) | 2003-02-28 | 2009-11-27 | Florey Howard Inst | Therapeutic compositions comprising an aryl sulphonate such as suramin, for the treatment of a pathological condition or event of the systemic vasculature resulting form the producation of reactive oxygen species. |
| EP1616576A4 (en) | 2003-04-08 | 2010-02-10 | Mitsubishi Tanabe Pharma Corp | SPECIFIC NAD (P) H OXIDASE HEMMER |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| RU2266906C1 (ru) * | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
| CA2582674A1 (en) | 2004-10-04 | 2006-04-20 | Myriad Genetics, Inc. | Compounds for alzheimer's disease |
| FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| US20070014739A1 (en) | 2005-07-14 | 2007-01-18 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
| DE102005048897A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| US20090099179A1 (en) | 2006-04-04 | 2009-04-16 | Myriad Genetics, Incorporated | Compounds for diseases and disorders |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
| PE20091093A1 (es) | 2007-12-03 | 2009-08-25 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
| FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2361912A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
-
2009
- 2009-09-28 EP EP09171466A patent/EP2305679A1/en not_active Withdrawn
-
2010
- 2010-09-27 ES ES10782688.5T patent/ES2644857T3/es active Active
- 2010-09-27 WO PCT/IB2010/054329 patent/WO2011036651A1/en not_active Ceased
- 2010-09-27 BR BR112012004208A patent/BR112012004208A2/pt not_active Application Discontinuation
- 2010-09-27 CA CA2770278A patent/CA2770278C/en not_active Expired - Fee Related
- 2010-09-27 PL PL10782688T patent/PL2483271T3/pl unknown
- 2010-09-27 RU RU2012117796/04A patent/RU2569855C2/ru not_active IP Right Cessation
- 2010-09-27 CN CN201080041718.5A patent/CN102686590B/zh not_active Expired - Fee Related
- 2010-09-27 NO NO10782688A patent/NO2483271T3/no unknown
- 2010-09-27 SI SI201031580T patent/SI2483271T1/en unknown
- 2010-09-27 ME MEP-2017-258A patent/ME03040B/me unknown
- 2010-09-27 PT PT107826885T patent/PT2483271T/pt unknown
- 2010-09-27 US US13/394,904 patent/US9394306B2/en not_active Expired - Fee Related
- 2010-09-27 HR HRP20171638TT patent/HRP20171638T1/hr unknown
- 2010-09-27 DK DK10782688.5T patent/DK2483271T3/da active
- 2010-09-27 LT LTEP10782688.5T patent/LT2483271T/lt unknown
- 2010-09-27 JP JP2012530402A patent/JP5707406B2/ja not_active Expired - Fee Related
- 2010-09-27 AU AU2010299487A patent/AU2010299487B2/en not_active Ceased
- 2010-09-27 SM SM20170541T patent/SMT201700541T1/it unknown
- 2010-09-27 RS RS20171071A patent/RS56542B1/sr unknown
- 2010-09-27 EP EP10782688.5A patent/EP2483271B1/en active Active
- 2010-09-27 HU HUE10782688A patent/HUE035058T2/en unknown
- 2010-09-27 KR KR1020127007664A patent/KR101791273B1/ko not_active Expired - Fee Related
-
2012
- 2012-03-25 IL IL218814A patent/IL218814A0/en unknown
-
2017
- 2017-11-03 CY CY20171101161T patent/CY1119780T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013505930A (ja) | 2013-02-21 |
| ME03040B (me) | 2018-10-20 |
| CN102686590A (zh) | 2012-09-19 |
| JP5707406B2 (ja) | 2015-04-30 |
| WO2011036651A1 (en) | 2011-03-31 |
| PT2483271T (pt) | 2017-11-15 |
| NO2483271T3 (enExample) | 2018-01-13 |
| EP2483271B1 (en) | 2017-08-16 |
| EP2483271A1 (en) | 2012-08-08 |
| HK1171748A1 (zh) | 2013-04-05 |
| IL218814A0 (en) | 2012-06-28 |
| HRP20171638T1 (hr) | 2017-12-01 |
| ES2644857T3 (es) | 2017-11-30 |
| PL2483271T3 (pl) | 2018-02-28 |
| KR20120090998A (ko) | 2012-08-17 |
| LT2483271T (lt) | 2017-11-10 |
| SMT201700541T1 (it) | 2018-01-11 |
| CA2770278C (en) | 2018-08-14 |
| CA2770278A1 (en) | 2011-03-31 |
| RU2012117796A (ru) | 2013-11-20 |
| RS56542B1 (sr) | 2018-02-28 |
| US20120172352A1 (en) | 2012-07-05 |
| CN102686590B (zh) | 2015-09-16 |
| EP2305679A1 (en) | 2011-04-06 |
| AU2010299487A1 (en) | 2012-03-29 |
| DK2483271T3 (da) | 2017-11-27 |
| HUE035058T2 (en) | 2018-05-02 |
| AU2010299487B2 (en) | 2016-03-24 |
| BR112012004208A2 (pt) | 2016-03-29 |
| US9394306B2 (en) | 2016-07-19 |
| KR101791273B1 (ko) | 2017-10-27 |
| CY1119780T1 (el) | 2018-09-05 |
| RU2569855C2 (ru) | 2015-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2483271T1 (en) | PIRAZOLIN DIOACTIVE DERIVATIVES AS NADPH-OXIDESHHAN INHIBITORS | |
| CY1126367T1 (el) | Παραγωγο βενζαζεπινης, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτης | |
| JOP20190143A1 (ar) | مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| SI2797921T1 (en) | Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors | |
| MX2010001677A (es) | Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli | |
| JP2013505930A5 (enExample) | ||
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| HRP20160647T1 (hr) | Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja | |
| AR081587A1 (es) | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) | |
| AR067869A1 (es) | Derivados de piridina y pirimidina | |
| HRP20170104T1 (hr) | Derivati tipa azaindazola ili diazaindazola za liječenje boli | |
| MX379459B (es) | Inhibidores de bromodominios. | |
| SI2751083T1 (en) | Quinolone compound | |
| NZ712378A (en) | Synthetic methods for spiro-oxindole compounds | |
| WO2007044050A3 (en) | 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
| PE20090235A1 (es) | Compuestos heterociclicos nitrogenados antibacterianos y su preparacion | |
| SI3166925T1 (en) | Isoindoline derivatives for use in treating a viral infection | |
| GEP20207128B (en) | Aminothiazole derivatives useful as antiviral agents | |
| WO2007064553A3 (en) | Thiazole derivatives as cxcr3 receptor modulators | |
| EA201691934A1 (ru) | Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1 | |
| WO2019178590A1 (en) | Heterocyclic inhibitors of atr kinase |